Course Objectives

Upon completion of this course, participants should be able to:

Examine new evidence for understanding the pathophysiology in nonexudative age-related macular degeneration
Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration
Evaluate emerging therapies for the treatment of nonexudative age-related macular degeneration with a particular focus on complement inhibitors and the population most likely to benefit once these drugs are approved
Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration
Evaluate the clinical use of available anti-VEGF drugs for exudative ocular diseases
Provide an update on the next generation of anti-VEGF therapies recently approved and currently in development
Evaluate the benefits and limitations of different imaging technologies in the diagnosis and clinical management of macular and retinal diseases
Incorporate the latest advances in artificial intelligence, specifically machine learning, for the diagnosis and treatment of retinal diseases